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Migraine has been estimated to be the seventh highest
cause of disability worldwide, and the third most common
disease worldwide after dental caries and tension type
headache. However, the use of currently available acute
and prophylactic medications to control this condition,
such as 5-HT1 agonists (triptans) and beta-blockers, is
limited by side effects and efficacy so that alternative and
more specific treatments are required. More recently, an
improved understanding of the pathophysiology of disease
has allowed investigation of new therapeutic targets.
The 37 amino acid neuropeptide calcitonin gene-related
peptide (CGRP) has been shown to play a crucial role in
the trigeminocervical complex pathway for nociception in
the head. Studies have demonstrated elevated levels in the
external jugular vein during the headache phase of
migraine, with reduction following headache resolution.
Furthermore, CGRP infusion triggers migraine type head-
ache and subsequent treatment with triptans results in
normalization of CGRP levels. This neuropeptide is
therefore thought to have a central role in pain modulation
as it participates in the neurovascular pathway and con-
tributes to the vasodilation and neurogenic inflammation,
which leads to migrainous attacks. Targeting CGRP may
provide the ideal therapeutic tool needed for control of this
common and debilitating illness.
The three studies chosen for this month’s journal club
are a small sample of the large amount of research being
performed on CGRP. The first investigates whether its
measurement can be used to classify migraine. The second
and third articles are phase II clinical trials which inves-
tigate the use of CGRP antagonists and a monoclonal
antibody CGRP.
Interictal increase in CGRP levels in peripheral
blood as a biological marker for chronic migraine
In this study, the authors investigated the possible use of
CGRP as a marker for chronic migraine. 103 female
patients diagnosed with chronic migraine according to
international headache society criteria were recruited.
Cases reported an average of 9.5 ± 3.4 years of chronic
migraine and attempted detoxification at least once for a
minimum of 2 months if diagnosed with analgesic overuse
migraine. The control groups consisted of 31 healthy
women with no headaches and on no medications, 43
females with episodic migraine, and 14 patients with
cluster headaches (13 female, 1 male).
Morning blood samples were taken from all patients on
days without moderate/severe headaches. No symptomatic
medications were allowed in the previous 24 h and pro-
phylactic medications were continued. CGRP was found to
be significantly higher in chronic migraine as compared to
all control groups interictally. The authors subsequently
analyzed the potential of CGRP as a biomarker for chronic
migraine and concluded that for a CGRP concentration of
43.45 ng/ml, 90.38 % of CM, and 80.64 % of controls
would be correctly classified. They also propose that it is
possible to distinguish between chronic migraine and epi-
sodic migraine on the CGRP level alone.
Comment. Although these findings demonstrate consid-
erable potential for CGRP levels as a disease biomarker,
considerably more evidence is required before it could be
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used in clinical practice. Sensitivity and specificity remains
poor, and its value in the clinical setting remains unclear
particularly as the IHS guidelines appear to provide clear
guidance for the clinician. Furthermore, the choice of
control groups is limited and it would be of interest to
extend these groups to include cases more representative of
general clinical practice. However, the study underlines the
relevance of CGRP in pathophysiology and holds promise
as an objective measure of response and of treatment
stratification for future therapeutic trials and also those
trials specifically targeting this molecule.
Cernuda-Morollo´n V et al (2013) Neurology
81:1191–1196.
BMS-927711 for the acute treatment of migraine:
a double-blind, randomized, placebo controlled,
dose-ranging trial
Previous studies of CGRP antagonists have been limited by
early termination due to liver toxicity. This well-designed,
single-dose, double-blind, randomized, multicenter evalu-
ation of the CGRP antagonist BMS-927711 measures
efficacy as an acute migraine therapy. 1026 patients were
enrolled and 885 randomized to receive a single dose of
placebo, 100 mg sumatriptan, or one of 6 different doses of
BMS-927711 (10, 25, 75, 150, 300 or 600 mg). Exclusion
criteria included a history of vascular disease and the
concomitant use of drugs metabolized by CYP3A. Pro-
phylactic migraine therapy was allowed but the use of other
acute therapies was prohibited 2 days prior to randomiza-
tion. A Bayesian analysis of the observed response rates
allocated groups to the more effective doses of BMS-
927711 as the trial progressed.
32.9 % of subjects on the 150 mg dose achieved pain
freedom at 2 h post-dose. Sumatriptan and the 75, 150, and
300 mg doses of BMS-927711 were all significantly
superior to placebo (\0.001, and \0.002, respectively).
The 600 mg dose did not provide any additional benefits.
Total migraine freedom was primarily achieved by the
75 mg dose (28.2 % of patients). The authors also explored
additional efficacy endpoints such as pain relief, sustained
pain relief and pain freedom over 2–48 h—all of which
were achieved by sumatriptan and the 75, 150, 300 and
600 mg doses of BMS-927711.
The antagonist was overall well tolerated with a dose-
related effect of nausea being the most reported adverse
event. Cardiovascular side effects were only reported by
patients on sumatriptan.
Comment. The lack of a vasoconstricting effect is a
significant advantage compared to currently available 5-HT
antagonists, although will need to be evaluated in patients
with known ischaemic heart disease. Importantly, the
authors point out that a single dose study does not provide a
full side effect profile, and adverse events such as liver
toxicity may only be evident with frequent use (as was the
case with previous CGRP antagonist). The study was not
powered to compare sumatriptan to BMS-927711, but
efficacy versus placebo seemed to be comparable. Further
studies are clearly needed and it will be interesting to
consider whether CGRP antagonists may have a specific
position in the treatment of the estimated 30 % of triptan
non-responders.
Marcus R et al (2014) Cephalalgia 34(2):114–125.
Safety, tolerability, and efficacy of TEV-48125
for preventive treatment of high-frequency
episodic migraine: a multicentre, randomized,
double-blind, placebo-controlled, phase 2b study
In this study, Bigal et al. report the results of two ran-
domized, double-blind, placebo controlled phase 2b trials
of a humanized monoclonal antibody targeting CGRP. This
exciting new therapy raises the possibility for a new era for
targeted migraine management. The study specifically
included patients using preventative drugs and acute ther-
apies, including occasional opioids, making it representa-
tive of resistant migraine and routine clinical practice.
297 patients experiencing 8–14 headache days in a
month, who could comply with the electronic headache
diary, were randomized in a 1:1:1 ratio of two doses of
TEV 48125 (225 and 675 mg) or placebo, given subcuta-
neously every 28 days for 3 months. A concomitant study
was performed by the same group on chronic migraineurs.
By the third treatment cycle, TEV 48125 reduced the
number of migraine days from baseline by 6.09 (SD 5.22)
days in the 675 mg group and by 6.27 (SD 5.38) days in the
225 mg group. As in other migraine trials, a high placebo
effect was present with a reduction of 3.46 migraine days.
Acute drug consumption, headache days, headache hours,
nausea and vomiting, photophobia and phonophobia were
also significantly reduced with both doses. The monoclonal
antibody was found to be safe with only mild injection site
reactions reported.
Comment. The effectiveness and tolerability of the
monoclonal antibody against CGRP, especially in patients
with severe migraine, is particularly promising. Since
monoclonal antibodies are too large to cross the (undis-
rupted) blood brain barrier, the results suggest that there is
a significant peripheral therapeutic effect. Overall, the
results seem very promising and reinforce the need for
further trials to study the long-term safety profile of this
drug, although whether the economics will make wide-
spread use likely or possible will need to be explored.
Bigal ME et al (2015) Lancet Neurol 14:1081–1090
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Conclusion. The neuropeptide CGRP is an intriguing
target for the management of migraine, which may well
change the current landscape of therapeutic options. CGRP
is, however, only one of several neuropeptides involved in
the trigeminocervical neuroinflammatory process (along
with VIP, glutamate, etc.) and it is therefore likely that
targeting this molecule will only prove effective for a
limited number of patients, as indeed is the case with
sumatriptan. However, it is likely to be of considerable
benefit to patients who do not tolerate 5-HT antagonists.
More research into the targeting of this molecule is needed,
but a more complete solution for the disability relating to
migraine might be possible.
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